LAUSR

Purpose: To determine the role of a single cycle of topical azithromycin in preventing long‐term trachoma complications in children from an area with endemic trachoma. Design: A longitudinal cohort study. Methods: Two hundred thirty‐eight (n = 238) children with active trachoma were enrolled in the current study. They were aged 1 to 10 years, with trachomatous inflammation based on the simplified World Health Organization grading system. These children were identified out of a survey of 8600 children from 7 villages in Punjab, Pakistan, where trachoma was endemic. The studied patients with active trachoma were treated with a single regimen of azithromycin 1.5% eye drops, given twice daily for 3 days, and were followed up for 3 years. The long‐term effects of this therapy were documented for the first time in an endemic area. Results: Two hundred fourteen children (90%) were present at 1‐year follow‐up with 10% dropout, and 178 (75%) were present at 3‐year follow‐up with 25% dropout. Of these, 23% and 11% had active trachoma at 1 and 3 years, respectively. Active trachoma was minimized from 100% at baseline to 11% at the end of 3 years. The reinfection rate was 4%. None of the patients developed trachoma‐related ocular complications during the study period. Conclusions: A single cycle of topical azithromycin can be used as an effective and safe option for treating active trachoma in children in endemic areas. This study also documented that a single cycle of topical azithromycin prevents trachoma‐related ocular complications in an endemic area.